Concord Biotech Ltd

NSE: CONCORDBIO · BSE: 543960 · Pharmaceuticals & Biotechnology · 27 announcements

Share price: ₹1,361.20
Market cap: ₹14,240 Cr
Revenue (annual): ₹1,055 Cr
Net profit (annual): ₹260.9 Cr
P/E (TTM): 51.7×Sector 47.4×
Promoter holding: 44.08%+0.00% QoQ
FII holding: 7.53%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Earnings Call 5 Regulatory Approval 3 Other Announcement 3 Financial Results 3 Board Meeting Date 3 Business Update 2 Bonus Issue 2 Annual General Meeting 2 Management Change 1 Legal & Regulatory 1 Dividend 1 Annual Report 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

3 announcements with these filters

31 Jul 2026 18:14 IST BSE

Financial Results

Concord Biotech Q1 FY27 Results: Net Profit ₹57.7 Cr, Up 30.8% YoY

Concord Biotech Ltd reported revenue from operations of ₹257.5 Cr (+26.2% YoY) and net profit of ₹57.7 Cr (+30.8% YoY) for Q1 FY27.

Key figure: Net profit ₹57.7 Cr · +30.8% YoY

Open full results → Read the filing ↗

29 May 2026 18:19 IST BSE

Financial Results

Concord Biotech Q4 FY26 Results: Net Profit ₹88.5 Cr, Down 37.0% YoY

Concord Biotech Ltd reported revenue from operations of ₹326.1 Cr (-24.1% YoY) and net profit of ₹88.5 Cr (-37.0% YoY) for Q4 FY26.

Key figure: Net profit ₹88.5 Cr · -37.0% YoY

Open full results → Read the filing ↗

29 May 2026 18:18 IST BSE

Financial Results

Concord Biotech Financial Results

Concord Biotech approved its FY26 audited financial results and recommended a final dividend of Rs. 7.55 per share. It also appointed Mrs. Ekta Gupta as an Additional Independent Director.

Read the filing ↗